Aprecia, the 3DP Pharmaceutical Company, has appointed Kathi Rinesmith, R.Ph., MS as senior vice president of regulatory affairs. Rinesmith will lead the company’s regulatory strategy, objectives, policies and programs pertaining to the development and marketing of drug products manufactured with Aprecia’s proprietary three-dimensional printing (3DP) technology platform, ZipDose Technology.
 
Rinesmith brings more than thirty years of experience related to the development and registration of pharmaceutical products ranging from early and late-stage product development, product approvals, and life-cycle management across several therapeutic areas.
 
Prior to joining Aprecia, Rinesmith served as director of global regulatory affairs and global pharmacovigilance at the specialty CDMO company Adare Pharmaceuticals. Earlier in her career, Rinesmith held senior executive product development and regulatory roles at Camargo Pharmaceutical Services, Prasco Laboratories, Barr Labs and Duramed Pharmaceuticals.
 
“Kathi has comprehensive experience and qualifications that will be instrumental in advancing Aprecia’s pipeline and will be a resource for our partners to achieve regulatory and commercial success,” said Aprecia CEO, Chris Gilmore. “Her leadership and strategic vision will enhance the future of Aprecia.”